Bharatt Chowrira, JD, PhD, has been the President and Chief of Business and Strategy at PureTech since March 2017. Prior to joining PureTech, Dr. Chowrira was the President of Synlogic, a biopharmaceutical company focused on developing synthetic microbiome-based therapeutics, from September 2015 to February 2017, where he oversaw and managed corporate and business development, alliance management, financial, human resources, intellectual property and legal operations. Prior to joining Synlogic, Dr. Chowrira was the Chief Operating Officer of Auspex Pharmaceuticals from 2013 to 2015, which was acquired by Teva Pharmaceuticals in the Spring of 2015. Previously, he was President and Chief Executive Officer of Addex Therapeutics from 2011 to 2013, a biotechnology company publicly-traded on the SIX Swiss Exchange. Prior to that Dr. Chowrira held various leadership and management positions at Nektar Therapeutics (COO), Merck & Co (VP), Sirna Therapeutics (GC; acquired by Merck &Co) and Ribozyme Pharmaceuticals (Chief Patent Counsel). Dr. Chowrira is currently a member of the board of directors of Akili Interactive and Karuna Therapeutics, Inc. Dr. Chowrira received a JD from the University of Denver’s Sturm College of Law, a PhD in Molecular Biology from the University of Vermont College of Medicine, an MS in Molecular Biology from Illinois State University and a BS in Microbiology from the UAS, Bangalore, India.

Joep Muijrers, PhD, is the Chief Financial Officer at PureTech. Dr. Muijrers has two decades of experience in corporate and capital finance, specifically focused on public market investment, M&A, portfolio management, strategic asset allocation, financial and regulatory reporting, and fundraising. Prior to joining PureTech, he was a Portfolio Manager and Partner at LSP (Life Sciences Partners), a trans-Atlantic investor group with exclusive focus on life sciences. At LSP, Dr. Muijrers was responsible for investing in publicly-traded companies, a strategy that generated a total return in excess of 900%, more than twice the return of the Nasdaq Biotechnology Index during the same period (Q2 2008 - Q1 2018). Notable investments included companies that were acquired by large pharma (Ablynx, Colucid, InterMune, Kite Pharma, NeuroDerm) and/or became leaders in their respective areas of activity (Evotec, Genmab, GW Pharmaceuticals, MorphoSys, Neurocrine). Prior to joining LSP, he held the position of Director Corporate Finance and Capital Markets at Fortis Bank, currently part of ABN AMRO. Dr. Muijrers holds a PhD degree in Molecular Biology from the European Molecular Biology Laboratory (EMBL) in Heidelberg, Germany and a Master’s degree in Biochemistry from the University of Nijmegen, The Netherlands.

Daphne Zohar is the Founder and Chief Executive Officer of PureTech and a member of the Board of Directors. PureTech is a clinical stage biotechnology company discovering, developing and commercializing highly differentiated medicines for devastating diseases including intractable cancers, lymphatic and gastrointestinal diseases, central nervous system disorders and inflammatory and immunological diseases. PureTech has a broad and deep pipeline created through the expertise of both PureTech’s experienced research and development team and its extensive network of scientists, clinicians and industry leaders. Through this network and relationships, PureTech generated the underlying programs and platforms that have resulted in a substantial pipeline comprised of one FDA-cleared product and 24 product candidates, which includes 14 in clinical trials. Zohar created PureTech, assembling a leading team to help implement her vision for a new model of biotherapeutic development which is entrepreneurial and agile, aligned with shareholders in advancing or deprioritizing programs in a capital efficient manner, and non-binary due to the breadth and depth of the pipeline. She has been a key participant in the creation of each of the programs in PureTech’s pipeline. Zohar has been recognized as a top leader and innovator in biotechnology by a number of sources, including EY, BioWorld, MIT's Technology Review, the Boston Globe, and Scientific American.